BROKERS CHOICE: TATACONSUM, BHARTIAIR, RADICO, LARSEN, ICICI, RBLBNK, SBIN, HAL, DIXON, NESTLE, COCHINSHIP

MUMBAI, 25 SEPTEMBER:

GS on Tata Consumer: Maintain Buy on Company, raise target price at Rs 1290 (Positive)

CLSA on Bharti Airtel: Maintain Outperform on Company, target price at Rs 2035 (Positive)

Jefferies on Radico: Maintain Buy on Company, target price at Rs 3590 (Positive)

MOSL on L&T: Maintain Buy on Company, raise target price at Rs 4300 (Positive)

MOSL on Gland Pharma: Maintain Buy on Company, target price at Rs 2340 (Positive)

Investec on ICICI Bank: Maintain Buy on Bank, target price at Rs 1745 (Positive)

Citi on RBL Bank: Maintain Buy on Bank, target price at Rs 300 (Positive)

Citi on SBIN: Maintain Buy on Bank, target price at Rs 1050 (Positive)

Avendus on Niva Bupa: Maintain Add on Company, target price at Rs 90 (Positive)

CLSA on HAL: Maintain Outperform on Company, target price at Rs 5436 (Positive)

Incred on Piramal Pharma: Maintain Buy on Company, target price at Rs 276 (Positive)

UBS on Dixon tech: Upgrade to Buy on Company, target price at Rs 23000 (Positive)

HSBC on Marico: Maintain Buy on Company, target price at Rs 870 (Positive)

HSBC on Godrej CP: Maintain Buy on Company, target price at Rs 1470 (Positive)

HSBC on Nestle: Upgrade to Hold on Company, raised target price at Rs 1270 (Positive)

HSBC on Britannia: Upgrade to Hold on Company, raised target price at Rs 6140 (Positive)

HSBC on Consumer Sector: See the consumer sector recovering from here driven by a favourable base, income tax cuts & GST rate reductions. (Positive)

MOSL on PSU Banks: PSU Banks well-positioned to sustain around 1% RoA, strong liquidity & funding profiles support stable credit growth. SBI, PNB, Indian Bank are top picks (Positive)

HSBC on Consumer Finance: Spends growth in August 2025 showed marginal improvement, data for September 2025 suggests robust growth in spends. HDFC Bank is seeing market share gains in both CIF & spends (Positive)

Incred on Cement Sector: Channel check showed cement industry passing on GST cut benefit (Positive)

Jefferies on India Strategy: India is now a consensus Underweight for foreign investors. Given sharp underperformance YTD, focus is on bottom-up ideas to reduce the Underweight (Neutral)

Citi on India Strategy: Communicating a “dovish pause” might be more difficult, ending up being a “wait and watch” policy (Neutral)

Nuvama on Sun Pharma: Maintain Hold on Company, target price at Rs 1830 (Neutral)

Kotak on Cyient: Maintain Reduce on Company, target price at Rs 1180 (Neutral)

Nomura on Glenmark Pharma: Maintain Neutral on Company, target price at Rs 1500 (Neutral)

Kotak on Cochin Shipyards: Maintain Sell on Company, target price at Rs 860 (Neutral)

(Disclaimer: The information provided here is investment advice only. Investing in the markets is subject to risks and please consult your advisor before investing.)

(સ્પષ્ટતા: અત્રેથી આપવામાં આવતી તમામ પ્રકારની માહિતી કોઇપણ પ્રકારે રોકાણ/ ટ્રેડીંગ માટેની સલાહ નથી. બજારોમાં રોકાણ જોખમોને આધીન છે અને રોકાણ કરતા પહેલા કૃપા કરીને તમારા સલાહકારની સલાહ લો.)